FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655663> ?p ?o ?g. }

• W4385655663 endingPage "e6096515" @default.
• W4385655663 startingPage "e6096515" @default.
• W4385655663 abstract "Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Diffuse large B-cell lymphoma (DLBCL) accounts for around one-third of all newly diagnosed non-Hodgkin lymphomas and 20–50% of patients will relapse or be refractory (R/R) to induction treatment. New treatments have significantly improved outcomes for patients in the third-line setting and beyond (≥3L). Large-scale, patient-level, real-world (RW) evidence studies can provide a good understanding of outcomes with currently available therapies in routine clinical practice and contextualize results from uncontrolled, single arm clinical trials. Aims: The ORCHID study aims to characterize RW treatment patterns and outcomes in a large cohort of ~700 patients with R/R DLBCL initiating ≥3L systemic therapy from over 30 clinical sites in 12 countries across North America, Europe, and Asia. Among them, an analytic cohort will be created of ~300 patients who have measurable disease at baseline and PET/CT scans during follow-up, unless they died. Methods: ORCHID (NCT05338892) is an electronic medical record-based observational, retrospective cohort study of patients with R/R DLBCL who have received ≥2 prior lines of systemic therapy, including an anti-CD20 antibody and an alkylator. The study population will be selected based on similar eligibility criteria as the R/R DLBCL arm of the odronextamab ELM-2 trial (NCT03888105; Figure). Patients must have measurable disease and have initiated ≥1 additional line of systemic therapy (salvage therapy) between Jan 01, 2015 and Jun 30, 2021 (indexing period) after meeting the criteria for R/R DLBCL. ORCHID is designed to contextualize outcomes from patients with R/R DLBCL enrolled in contemporaneous single-arm studies. To estimate RW objective response rate (ORR) by independent central review (ICR), analytical cohorts will be created from the ORCHID population based on data requirements and matching feasibility. Patients will be propensity score matched and/or weighted to each patient in the ELM-2 trial (anticipated cohort, n=127). To identify prognostic variables for inclusion in the propensity score model, a systematic literature review was conducted (PROSPERO CRD42022307557) and findings were ranked by three key opinion leaders. The most important prognostic variables identified included early chemoimmunotherapy failure, Eastern Cooperative Oncology Group performance status, refractory to last line of therapy, number of prior treatment lines, double or triple-hit lymphoma, age, International Prognostic Index, Ann Arbor stage, and lactate dehydrogenase. Results: The primary endpoint of ORCHID is ICR-assessed ORR (Lugano classification). Secondary outcomes include physician-assessed ORR as well as complete response rate, progression-free survival, duration of response, and disease control rate assessed by ICR and treating physician. Overall survival and time to next treatment will also be evaluated. Subgroups of interest will include historical (Jan 01, 2015 to Nov 12, 2019) versus contemporary treatment (Nov 13, 2019 to Jun 30, 2021), chimeric antigen receptor (CAR)-T cell therapy versus other salvage regimens, and geographic region. Sensitivity analyses will be conducted in expanded cohorts to assess the impact of eligibility criteria and availability of scans. Summary/Conclusion: When complete, ORCHID will provide important current information on the RW outcomes of patients with DLBCL and provide a valuable source of control data for comparative studies in R/R DLBCL.Keywords: Non-Hodgkin’s lymphoma, Relapsed lymphoma, Diffuse large B cell lymphoma, Real world data" @default.
• W4385655663 created "2023-08-09" @default.
• W4385655663 creator A5000480591 @default.
• W4385655663 creator A5004596365 @default.
• W4385655663 creator A5004806314 @default.
• W4385655663 creator A5013810224 @default.
• W4385655663 creator A5017763514 @default.
• W4385655663 creator A5021882401 @default.
• W4385655663 creator A5027355800 @default.
• W4385655663 creator A5029013179 @default.
• W4385655663 creator A5032499598 @default.
• W4385655663 creator A5033073385 @default.
• W4385655663 creator A5044166963 @default.
• W4385655663 creator A5047329021 @default.
• W4385655663 creator A5053019069 @default.
• W4385655663 creator A5060974199 @default.
• W4385655663 creator A5061172842 @default.
• W4385655663 creator A5062422990 @default.
• W4385655663 creator A5067929449 @default.
• W4385655663 creator A5072586223 @default.
• W4385655663 creator A5073670393 @default.
• W4385655663 creator A5085689787 @default.
• W4385655663 date "2023-08-01" @default.
• W4385655663 modified "2023-09-30" @default.
• W4385655663 title "PB2357: TRIAL IN PROGRESS: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH SYSTEMIC THERAPY FROM REAL-WORLD EXPERIENCE (ORCHID)" @default.
• W4385655663 doi "https://doi.org/10.1097/01.hs9.0000976144.60965.15" @default.
• W4385655663 hasPublicationYear "2023" @default.
• W4385655663 type Work @default.
• W4385655663 citedByCount "0" @default.
• W4385655663 crossrefType "journal-article" @default.
• W4385655663 hasAuthorship W4385655663A5000480591 @default.
• W4385655663 hasAuthorship W4385655663A5004596365 @default.
• W4385655663 hasAuthorship W4385655663A5004806314 @default.
• W4385655663 hasAuthorship W4385655663A5013810224 @default.
• W4385655663 hasAuthorship W4385655663A5017763514 @default.
• W4385655663 hasAuthorship W4385655663A5021882401 @default.
• W4385655663 hasAuthorship W4385655663A5027355800 @default.
• W4385655663 hasAuthorship W4385655663A5029013179 @default.
• W4385655663 hasAuthorship W4385655663A5032499598 @default.
• W4385655663 hasAuthorship W4385655663A5033073385 @default.
• W4385655663 hasAuthorship W4385655663A5044166963 @default.
• W4385655663 hasAuthorship W4385655663A5047329021 @default.
• W4385655663 hasAuthorship W4385655663A5053019069 @default.
• W4385655663 hasAuthorship W4385655663A5060974199 @default.
• W4385655663 hasAuthorship W4385655663A5061172842 @default.
• W4385655663 hasAuthorship W4385655663A5062422990 @default.
• W4385655663 hasAuthorship W4385655663A5067929449 @default.
• W4385655663 hasAuthorship W4385655663A5072586223 @default.
• W4385655663 hasAuthorship W4385655663A5073670393 @default.
• W4385655663 hasAuthorship W4385655663A5085689787 @default.
• W4385655663 hasBestOaLocation W43856556631 @default.
• W4385655663 hasConcept C121332964 @default.
• W4385655663 hasConcept C121608353 @default.
• W4385655663 hasConcept C126322002 @default.
• W4385655663 hasConcept C142424586 @default.
• W4385655663 hasConcept C143998085 @default.
• W4385655663 hasConcept C167135981 @default.
• W4385655663 hasConcept C185926286 @default.
• W4385655663 hasConcept C2776694085 @default.
• W4385655663 hasConcept C2778559949 @default.
• W4385655663 hasConcept C2779338263 @default.
• W4385655663 hasConcept C2780775027 @default.
• W4385655663 hasConcept C2908647359 @default.
• W4385655663 hasConcept C530470458 @default.
• W4385655663 hasConcept C535046627 @default.
• W4385655663 hasConcept C71924100 @default.
• W4385655663 hasConcept C72563966 @default.
• W4385655663 hasConcept C87355193 @default.
• W4385655663 hasConcept C99454951 @default.
• W4385655663 hasConceptScore W4385655663C121332964 @default.
• W4385655663 hasConceptScore W4385655663C121608353 @default.
• W4385655663 hasConceptScore W4385655663C126322002 @default.
• W4385655663 hasConceptScore W4385655663C142424586 @default.
• W4385655663 hasConceptScore W4385655663C143998085 @default.
• W4385655663 hasConceptScore W4385655663C167135981 @default.
• W4385655663 hasConceptScore W4385655663C185926286 @default.
• W4385655663 hasConceptScore W4385655663C2776694085 @default.
• W4385655663 hasConceptScore W4385655663C2778559949 @default.
• W4385655663 hasConceptScore W4385655663C2779338263 @default.
• W4385655663 hasConceptScore W4385655663C2780775027 @default.
• W4385655663 hasConceptScore W4385655663C2908647359 @default.
• W4385655663 hasConceptScore W4385655663C530470458 @default.
• W4385655663 hasConceptScore W4385655663C535046627 @default.
• W4385655663 hasConceptScore W4385655663C71924100 @default.
• W4385655663 hasConceptScore W4385655663C72563966 @default.
• W4385655663 hasConceptScore W4385655663C87355193 @default.
• W4385655663 hasConceptScore W4385655663C99454951 @default.
• W4385655663 hasIssue "S3" @default.
• W4385655663 hasLocation W43856556631 @default.
• W4385655663 hasLocation W43856556632 @default.
• W4385655663 hasOpenAccess W4385655663 @default.
• W4385655663 hasPrimaryLocation W43856556631 @default.
• W4385655663 hasRelatedWork W2351796763 @default.
• W4385655663 hasRelatedWork W2883371432 @default.
• W4385655663 hasRelatedWork W2891805083 @default.
• W4385655663 hasRelatedWork W2980482946 @default.
• W4385655663 hasRelatedWork W3040347271 @default.
• W4385655663 hasRelatedWork W4244641017 @default.

• next